Coronavirus Vaccine: The Bill & Melinda Gates Foundation will provide $150 million in risk investments to Gavi, the Vaccine Alliance, to the Serum Institute of India (SII) to drive the manufacture of potential applicants for the Covid-19 vaccine. Vaccines will be sold at a maximum value of $3 according to the dose and will be manufactured for 92 countries. The IBS will manufacture and distribute one hundred million doses by early 2021 for India and low- and middle-income countries.
SII, owned by Poonawalas, based in Pune, is the world’s largest manufacturer of bulk vaccines and works on several Covid-19 vaccines. SII was approved by DCG for phase 2 and 3 human trials for the Oxford University’s Covid-19 vaccine project. This test will cover another 1,600 people at 19 sites across India.
The IBS also entered into a licensing agreement with U.S. biotechnology company Novavax to manufacture and market Novavax’s corona vaccine in India and some other markets.
The IBS had committed its own resources and began painting the Covid-19 vaccine in April 2020 in the hope that trials of the Oxford human vaccine would succeed. It uses its existing services and will now manufacture five to ten million vaccines per month.
As vaccines obtain WHO regulatory approval and screening, large-scale doses can occur. The funding will be the production of ISY dicy for the candidate vaccines AstraZeneca and Novavax. The arrangement also offers the option to download more doses if needed.
Adar Poonawalla, EXECUTIVE director of IBS, said the deal would intensify efforts to save the lives of millions of people from this terrible disease. IBS has a long history of collaborating with Gavi and pharmaceutical companies to make vaccines that will prevent meningitis, severe diarrhea, pneumonia and measles. The IBS now has two vaccine production agreements. In addition to the ChAdOx1 vaccine from Oxford and AstraZenca, it has signed an agreement of origin and license with the US biotechnology company Novavax to manufacture and market the Novavax vaccine, the candidate vaccine NVX-CoV2373, for the SARS-CoV-2 virus. The two partners will have a revenue-sharing agreement.
The IBS has exclusive rights to the Covid-19 vaccine for India and non-exclusive rights during the pandemic era in all countries, unless they are high/high middle-income countries. This vaccine is in the initial testing phase.
Get live equity costs from BSE, NSE, U.S. market. And the latest liquidity value, mutual fund portfolio, calculate your taxes, the source of the income tax calculator, meet the most productive winners on the market, the most productive losers and the most productive equity funds. Like it on Facebook and stay with us on Twitter.
Financial Express is now on Telegram. Click here to subscribe to our channel and stay up to date with the latest News and Updates from Biz.